ArticleEuropean archives of psychiatry and clinical neuroscience2019
Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders.
Article in European archives of psychiatry and clinical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Identifying Transdiagnostic Predictors of Depression across Psychoses: Informing Stratified Antidepressant Treatments.Psychotherapy and psychosomatics · 2026Article
- Association of higher triglyceride glucose index and triglyceride to high density lipoprotein cholesterol ratio with early-onset post-stroke depression.Scientific reports · 2025Article
- AI-based prediction of depression symptomatology in first-episode psychosis patients: insights from the EUFEST and RAISE-ETP clinical trials.Psychological medicine · 2025Article
- Article
- Chronic Lung Diseases and Depressive Symptoms in Older Adults: Insights from Observational Studies and Mendelian Randomization.Journal of multidisciplinary healthcare · 2025Article
- Effect of RANKL on Lower Depressive Symptoms In Hemodialysis Patients.Calcified tissue international · 2024Article
- Article
- Lipid Biomarker Research in Bipolar Disorder: A Scoping Review of Trends, Challenges, and Future Directions.Biological psychiatry global open science · 2023Article
- Prevalence and clinical correlates of psychotic symptoms in first-episode untreated female chinese patients with major depressive disorder.BMC psychiatry · 2023Article
- Selected Parameters of Bone Turnover in Neuroendocrine Tumors-A Potential Clinical Use?Journal of clinical medicine · 2023Article
- Alterations in Plasma Lipidomic Profiles in Adult Patients with Schizophrenia and Major Depressive Disorder.Medicina (Kaunas, Lithuania) · 2022Article
- Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review.Frontiers in psychiatry · 2022Review
- Impact of the metabolic syndrome on severe mental disorders.European archives of psychiatry and clinical neuroscience · 2020Article
- Atherogenic Lipid Ratios Related to Myeloperoxidase and C-Reactive Protein Levels in Psychotic Disorders.Frontiers in psychiatry · 2020Article
- Multimodel inference for biomarker development: an application to schizophrenia.Translational psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Although the relationship between positive and negative symptoms of psychosis and dyslipidemia has been thoroughly investigated in recent studies, the potential link between depression and lipid status is still under-investigated. We here examined the association between lipid levels and depressive symptomatology in patients with psychotic disorders, in addition to their possible inflammatory associations. Participants (n = 652) with the following distribution: schizophrenia, schizophreniform and schizoaffective disorder (schizophrenia group, n = 344); bipolar I, II, NOS, and psychosis NOS (non-schizophrenia group, n = 308) were recruited consecutively from the Norwegian Thematically Organized Psychosis (TOP) Study. Clinical data were obtained by Positive and Negative Syndrome Scale (PANSS), and Calgary Depression Scale for Schizophrenia (CDSS). Blood samples were analyzed for total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), C-reactive protein (CRP), soluble tumor necrosis factor receptor 1(sTNF-R1), osteoprotegerin (OPG), and interleukin 1 receptor antagonist (IL-1Ra). After adjusting for age, gender, BMI, smoking, and dyslipidemia-inducing antipsychotics, TC and LDL scores showed significant associations with depression [β = 0.13, p = 0.007; β = 0.14, p = 0.007], and with two inflammatory markers: CRP [β = 0.14, p = 0.007; β = 0.16, p = 0.007] and OPG [β = 0.14, p = 0.007; β = 0.11, p = 0.007]. Total model variance was 17% for both analyses [F(12, 433) = 8.42, p < 0.001; F(12, 433) = 8.64, p < 0.001]. Current findings highlight a potential independent role of depression and inflammatory markers, CRP and OPG in specific, in the pathophysiology of dyslipidemia in psychotic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.